Sangamo Therapeutics (SGMO) EBITDA (2016 - 2025)
Historic EBITDA for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$35.6 million.
- Sangamo Therapeutics' EBITDA fell 43442.76% to -$35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.0 million, marking a year-over-year increase of 2214.54%. This contributed to the annual value of -$104.0 million for FY2024, which is 6205.58% up from last year.
- Per Sangamo Therapeutics' latest filing, its EBITDA stood at -$35.6 million for Q3 2025, which was down 43442.76% from -$17.9 million recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' EBITDA registered a high of $18.0 million during Q1 2023, and its lowest value of -$123.6 million during Q2 2023.
- For the 5-year period, Sangamo Therapeutics' EBITDA averaged around -$44.5 million, with its median value being -$45.7 million (2022).
- Per our database at Business Quant, Sangamo Therapeutics' EBITDA plummeted by 120872.74% in 2021 and then soared by 13984.45% in 2023.
- Over the past 5 years, Sangamo Therapeutics' EBITDA (Quarter) stood at -$39.9 million in 2021, then plummeted by 38.83% to -$55.4 million in 2022, then dropped by 12.04% to -$62.1 million in 2023, then skyrocketed by 58.12% to -$26.0 million in 2024, then crashed by 36.79% to -$35.6 million in 2025.
- Its last three reported values are -$35.6 million in Q3 2025, -$17.9 million for Q2 2025, and -$29.6 million during Q1 2025.